Oral MK-677 Restores Youthful Growth Hormone and IGF-1 Levels in Elderly Adults
Daily oral MK-677 significantly increased growth hormone and IGF-1 levels in healthy elderly adults to ranges seen in younger people, without serious side effects.
Quick Facts
What This Study Found
Daily oral MK-677 significantly stimulated the GH-IGF-1 axis in healthy elderly adults aged 64-81, raising levels toward those seen in younger individuals.
Key Numbers
How They Did This
Randomized controlled trial with 32 healthy elderly subjects (15 women, 17 men, aged 64-81). Participants received oral MK-677 daily, and GH and IGF-1 levels were measured.
Why This Research Matters
Declining growth hormone is associated with aging-related muscle loss, fat gain, and cardiovascular risk. An oral compound that safely restores youthful GH levels could have significant anti-aging applications.
The Bigger Picture
This study was pivotal in establishing MK-677 as a viable oral GH secretagogue for elderly populations, offering a more practical alternative to GH injections for combating age-related hormonal decline.
What This Study Doesn't Tell Us
Relatively small sample size. Short-term study; long-term effects and safety not established. Functional outcomes (muscle mass, strength, body composition) were not the primary endpoints.
Questions This Raises
- ?Does MK-677's GH stimulation translate to meaningful improvements in muscle mass and function in elderly adults?
- ?What are the long-term safety implications of chronically elevated GH/IGF-1 levels in aging populations?
Trust & Context
- Key Stat:
- Youthful GH levels restored Oral MK-677 raised GH and IGF-1 levels in elderly adults (64-81 years) toward ranges typical of younger individuals
- Evidence Grade:
- Strong evidence from a randomized controlled trial in human elderly subjects. Well-designed but relatively small and short-term.
- Study Age:
- Published in 1996, this was one of the earliest RCTs of oral MK-677 in elderly populations. Subsequent studies have confirmed and extended these findings.
- Original Title:
- Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects.
- Published In:
- The Journal of clinical endocrinology and metabolism, 81(12), 4249-57 (1996)
- Authors:
- Chapman, I M(3), Bach, M A(3), Van Cauter, E(3), Farmer, M, Krupa, D, Taylor, A M, Schilling, L M, Cole, K Y, Skiles, E H, Pezzoli, S S, Hartman, M L, Veldhuis, J D, Gormley, G J, Thorner, M O
- Database ID:
- RPEP-00357
Evidence Hierarchy
Frequently Asked Questions
What is MK-677?
MK-677 (ibutamoren) is an oral growth hormone secretagogue — it stimulates the body's own GH release by mimicking ghrelin at the GH secretagogue receptor. Unlike GH injections, it can be taken as a pill.
Why does growth hormone decline matter in aging?
Growth hormone and IGF-1 naturally decrease with age, contributing to muscle loss (sarcopenia), increased body fat, reduced bone density, and potentially increased cardiovascular risk. Restoring youthful levels may help counteract these changes.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00357APA
Chapman, I M; Bach, M A; Van Cauter, E; Farmer, M; Krupa, D; Taylor, A M; Schilling, L M; Cole, K Y; Skiles, E H; Pezzoli, S S; Hartman, M L; Veldhuis, J D; Gormley, G J; Thorner, M O. (1996). Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects.. The Journal of clinical endocrinology and metabolism, 81(12), 4249-57.
MLA
Chapman, I M, et al. "Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects.." The Journal of clinical endocrinology and metabolism, 1996.
RethinkPeptides
RethinkPeptides Research Database. "Stimulation of the growth hormone (GH)-insulin-like growth f..." RPEP-00357. Retrieved from https://rethinkpeptides.com/research/chapman-1996-stimulation-of-the-growth
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.